CPC-200, Colby's co-lead drug is being developed for a Phase l/lla clinical trial in 2009 as a therapeutic OSM drug for the treatment of prostate cancer recurring after surgical or radiation de-bulking of the primary tumor, prior to ADT.
CPC-200 is a small molecule drug that inhibits the catabolic oxidase enzyme reaction with its endogenous substrate, specifically present at high concentrations in the prostate. CPC-200 is a synthetic substrate analog drug that binds to and inactivates the oxidase, thus inhibiting hydrogen peroxide production specifically in the prostate epithelial cells. Therapeutic treatment with CPC-200 in experimental mouse models of prostate cancer show a significant overall survival benefit and decreased prostate cancer progression.
CPC-200 Mechanism of Action &
Effect of H2O2 inhibition by CPC-200
